Browsing Tag
AN2 Therapeutics
2 posts
AN2 Therapeutics reveals 40% 90-day mortality in NIH-backed melioidosis study, advancing epetraborole toward Phase 2 trial
AN2 Therapeutics reports high 90-day mortality in 200-patient NIH-funded melioidosis study, laying groundwork for Phase 2 epetraborole trial in 2025.
Shockwave through biotech: AN2 Therapeutics slashes workforce after trial fails
AN2 Therapeutics, Inc., a pioneering force in novel small molecule drugs, has announced a dramatic reduction of its…